Drug intelligence / Profile preview

Stablor

Development stage: Unknown
Lead developer: YSOPIA Bioscience
Administration: Oral

Overview

Stablor is a dietary supplement and medical food developed by LNC Therapeutics (also known as Laboratoires Nutrition et Cardiometabolisme). It is composed of specific proportions of amino acids, micronutrients, and milk proteins. Stablor is primarily indicated for the reduction of visceral fat mass and improvement of cardiometabolic risk factors in patients with metabolic syndrome and abdominal obesity. Clinical trials have been conducted to demonstrate its efficacy and safety, with ongoing studies aiming for an EFSA health claim.

Brand names: StablorStablor™

Beyond the preview

Go deeper on Stablor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stablor.

Explore the full profile